(Q38120288)

29 August 2017

Gastric cancer pharmacogenetics: progress or old tripe? (English)

1 reference

29 August 2017

2

Charles S Fuchs

1 reference

29 August 2017

Jai N Patel

1

1 reference

29 August 2017

Kouros Owzar

series ordinal

3

1 reference

29 August 2017

Zihua Chen

series ordinal

4

1 reference

29 August 2017

Howard L McLeod

series ordinal

5

1 reference

29 August 2017

1 July 2013

1 reference

29 August 2017

1 reference

29 August 2017

14

1 reference

29 August 2017

9

1 reference

29 August 2017

1053-1064

1 reference

Pharmacokinetics and pharmacogenomics in gastric cancer chemotherapy

29 August 2017

1 reference

Epidemiology of gastric cancer

21 January 2018

1 reference

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

21 January 2018

1 reference

Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancer

21 January 2018

1 reference

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

21 January 2018

1 reference

A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus

21 January 2018

1 reference

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

21 January 2018

1 reference

Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer

21 January 2018

1 reference

Folate intake along with genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase in patients with advanced gastric cancer

21 January 2018

1 reference

Detection of the G>C SNP and rare mutations in the 28-bp repeat of TYMS using gel-based capillary electrophoresis.

21 January 2018

1 reference

Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer

21 January 2018

1 reference

Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma.

21 January 2018

1 reference

Pharmacogenetics and stomach cancer: an update.

21 January 2018

1 reference

High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity

21 January 2018

1 reference

Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?

21 January 2018

1 reference

Should DPD analysis be required prior to prescribing fluoropyrimidines?

21 January 2018

1 reference

Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians

21 January 2018

1 reference

C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation

21 January 2018

1 reference

Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide

21 January 2018

1 reference

BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin

21 January 2018

1 reference

Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie

21 January 2018

1 reference

Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil

21 January 2018

1 reference

A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome

21 January 2018

1 reference

CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients

21 January 2018

1 reference

Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?

21 January 2018

1 reference

CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.

21 January 2018

1 reference

Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients

21 January 2018

1 reference

Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes

21 January 2018

1 reference

A comparison of cataloged variation between International HapMap Consortium and 1000 Genomes Project data

21 January 2018

1 reference

Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with esophageal adenocarcinoma risk

21 January 2018

1 reference

Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene

21 January 2018

1 reference

Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer.

21 January 2018

1 reference

Prediction of paclitaxel resistance in breast cancer: is CYP1B1*3 a new factor of influence?

21 January 2018

1 reference

Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.

21 January 2018

1 reference

Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity

21 January 2018

1 reference

Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?

21 January 2018

1 reference

UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil

21 January 2018

1 reference

A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer

21 January 2018

1 reference

Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer

21 January 2018

1 reference

Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms

21 January 2018

1 reference

Locally advanced and metastatic gastric cancer: current management and new treatment developments

21 January 2018

1 reference

Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer

21 January 2018

1 reference

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

21 January 2018

1 reference

Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer

21 January 2018

1 reference

Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO).

21 January 2018

1 reference

A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer

21 January 2018

1 reference

Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer

21 January 2018

1 reference

Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

21 January 2018

1 reference

Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer

21 January 2018

1 reference

A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients

21 January 2018

1 reference

Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer

21 January 2018

1 reference

Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients

21 January 2018

1 reference

Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial

21 January 2018

1 reference

Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer.

21 January 2018

1 reference

Polymorphism in the 3'-untranslated region of the thymidylate synthase gene and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy

21 January 2018

1 reference

Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients

21 January 2018

1 reference

Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer.

21 January 2018

1 reference

Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer

21 January 2018

1 reference

Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy

21 January 2018

1 reference

The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.

21 January 2018

1 reference

Polymorphism of thymidylate synthase gene and chemosensitivity of 5-fluorouracil regimen in metastatic gastrointestinal cancer.

21 January 2018

1 reference

Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker

21 January 2018

1 reference

Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity

21 January 2018

1 reference

Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6.

21 January 2018

1 reference

Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.

21 January 2018

1 reference

Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer

21 January 2018

1 reference

Dihydropyrimidine dehydrogenases and cytidine-deaminase gene polymorphisms as outcome predictors in resected gastric cancer patients treated with fluoropyrimidine adjuvant chemotherapy.

21 January 2018

1 reference

Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase

21 January 2018

1 reference

Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer.

21 January 2018

1 reference

Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.

21 January 2018

1 reference

Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer.

21 January 2018

1 reference

Expression of glutathione S-transferase-pi and sensitivity of human gastric cancer cells to cisplatin

21 January 2018

1 reference

Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer

21 January 2018

1 reference

DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy

21 January 2018

1 reference

ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/PGS.13.88

1 reference

29 August 2017

1 reference